Table 1 Histopathological and clinical parameters of patients with RCC
From: Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma
Patient characteristics | All RCC all tumours | % |
|---|---|---|
Total | 106 | 100% |
Patients | ||
Age (mean; ± SD) | 63.7 (11.8) | |
Male | 68 | 64.2% |
Female | 38 | 35.8% |
Histology | ||
Clear cell | 77 | 72.6% |
Papillary | 22 | 20.7% |
Chromophobe | 5 | 4.7% |
Other/not classified | 2 | 1.9% |
Stage | ||
NA | 3 | 2.8% |
pT1 | 9 | 8.5% |
pT1a | 32 | 30.2% |
pT1b | 20 | 18.9% |
pT2 | 5 | 4.7% |
pT3 | 3 | 2.8% |
pT3a | 10 | 9.4% |
pT3b | 24 | 22.6% |
pT4 | 0 | 0% |
Grade | ||
G1 | 17 | 16% |
G1-2 | 15 | 14.2% |
G2 | 57 | 53.8% |
G2-3 | 7 | 6.6% |
G3 | 10 | 9.4% |
LN metastasis* | 11 | 10.4% |
Visceral metastasis* | 23 | 21.7% |
advanced/metastatic disease | ||
(pT3-4 or N+/M+/>G2) | 49 | 46.2% |